Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 7,479 Shares

Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the sale, the general counsel owned 51,326 shares in the company, valued at approximately $1,010,608.94. This trade represents a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Urogen Pharma Stock Down 2.4%

Shares of URGN traded down $0.53 during trading hours on Wednesday, reaching $21.14. The stock had a trading volume of 594,277 shares, compared to its average volume of 701,856. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $30.00. The firm has a 50-day moving average of $21.78 and a 200 day moving average of $20.73. The company has a market cap of $989.54 million, a P/E ratio of -6.11 and a beta of 1.32.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. D. Boral Capital restated a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a report on Friday, January 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Urogen Pharma in a research report on Monday, October 27th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Urogen Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $33.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in URGN. Paradigm Biocapital Advisors LP bought a new stake in Urogen Pharma in the 3rd quarter valued at $84,111,000. Soleus Capital Management L.P. acquired a new position in shares of Urogen Pharma in the second quarter valued at $29,934,000. SG Americas Securities LLC increased its holdings in shares of Urogen Pharma by 19.0% in the fourth quarter. SG Americas Securities LLC now owns 1,377,647 shares of the company’s stock valued at $32,264,000 after purchasing an additional 220,264 shares during the last quarter. TCG Crossover Management LLC bought a new position in shares of Urogen Pharma in the third quarter valued at about $14,311,000. Finally, Orbimed Advisors LLC lifted its stake in shares of Urogen Pharma by 44.0% during the 3rd quarter. Orbimed Advisors LLC now owns 689,000 shares of the company’s stock worth $13,746,000 after buying an additional 210,600 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.